...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiac failure >Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.
【24h】

Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.

机译：阿托伐他汀治疗可增加晚期慢性心力衰竭患者的心率变异性，降低QT变异性并缩短QTc间隔时间。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Although statins decrease the incidence of ventricular arrhythmias in patients with atherosclerotic heart disease, their potential antiarrhythmic effects in heart failure remain undefined. METHODS AND RESULTS: Of 80 heart failure patients enrolled, 40 were randomized to receive atorvastatin (statin group); the remaining 40 served as controls. At baseline and after 3 months, we measured heart rate variability (HRV), QT variability (QTV), and QTc interval using interactive high-resolution electrocardiogram analysis. The 2 groups did not differ in baseline HRV standard deviation of normal-to-normal intervals (SDNN) (RR): 24.6 +/- 2.8 ms in statin group versus 24.8 +/- 3.1 ms in controls, P = .72; square root of the mean of squared differences between successive intervals (rMSSD) (RR): 21.2 +/- 2.7 ms versus 21.7 +/- 2.9 ms, P = .43), QTV SDNN (QT): 6.4 +/- 1.5 ms versus 6.4+/-1.7, P = .96; rMSSD QT): 9.0 +/- 2.4 ms versus 8.7 +/- 2.9 ms, P = .65, and QTc interval 450 +/- 30 ms versus 446 +/- 27 ms, P = .59. At 3 months, the statin group displayed higher HRV SDNN RR): 27.2 +/- 4.9 ms versus 24.4 +/- 2.8 ms in controls, P = .003; rMSSD RR: 24.7 +/- 4.2 ms versus 21.3 +/- 5.6 ms, P = .004, lower QTV SDNN (QT): 5.1 +/- 1.9 ms versus 6.5 +/- 2.1, P = .004; rMSSD (QT): 6.6 +/- 2.8 ms versus 8.8 +/- 3.1 ms, P = .002, and shorter QTc interval 437 +/- 29 ms versus 450 +/- 25 ms, P = .03 than the control group. CONCLUSIONS: Atorvastatin increases HRV, decreases QTV, and shortens QTc interval, and may thereby reduce the risk of arrhythmias in patients with advanced heart failure.
机译：背景：尽管他汀类药物降低了动脉粥样硬化性心脏病患者的室性心律失常的发生率，但其在心力衰竭中的潜在抗心律不齐作用仍然不确定。方法和结果：在80名心力衰竭患者中，有40名被随机分配接受阿托伐他汀（他汀类药物治疗）;其余40个用作对照。在基线和3个月后，我们使用交互式高分辨率心电图分析测量了心率变异性（HRV），QT变异性（QTV）和QTc间隔。两组正常/正常间隔（SDNN）（RR）的基线HRV标准差无差异：他汀类药物组为24.6 +/- 2.8 ms，对照组为24.8 +/- 3.1 ms，P = .72;连续间隔（rMSSD）（RR）之间的平方差均方根的平方根：21.2 +/- 2.7 ms与21.7 +/- 2.9 ms，P = 0.43），QTV SDNN（QT）：6.4 +/- 1.5 ms与6.4 +/- 1.7，P = 0.96; rMSSD QT）：9.0 +/- 2.4 ms与8.7 +/- 2.9 ms，P = 0.65，QTc间隔450 +/- 30 ms与446 +/- 27 ms，P = 0.59。他汀类药物组在3个月时显示出较高的HRV SDNN RR）：27.2 +/- 4.9毫秒，而对照组为24.4 +/- 2.8毫秒，P = .003; rMSSD RR：24.7 +/- 4.2 ms与21.3 +/- 5.6 ms，P = .004，较低的QTV SDNN（QT）：5.1 +/- 1.9 ms与6.5 +/- 2.1，P = .004; rMSSD（QT）：6.6 +/- 2.8 ms vs 8.8 +/- 3.1 ms，P = .002，QTc间隔更短437 +/- 29 ms vs 450 +/- 25 ms，P = .03 。结论：阿托伐他汀可增加HRV，降低QTV并缩短QTc间隔，从而可降低晚期心力衰竭患者发生心律不齐的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号